The U.S. Food and Drug Administration (FDA) issued its final guidance on mandatory cosmetics recalls on October 22, 2026, clarifying how the agency may exercise its recall authority under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
The document, titled Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry, explains the circumstances in which the FDA may order a cosmetics recall, the procedures involved and the expectations for affected businesses.
The final guidance follows a draft published on December 18, 2025. According to the FDA, no substantive changes were made after consideration of public comments.
When Can the FDA Order a Mandatory Recall?
Under Section 611 of the Federal Food, Drug, and Cosmetic Act, the FDA may exercise mandatory recall authority when it determines that:
- There is a reasonable probability that a cosmetic product is adulterated or misbranded.
- There is also a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death.
Both conditions must be satisfied for the agency to invoke this specific mandatory recall authority.
The guidance applies to products meeting the statutory definition of cosmetics. Products that are also regulated as drugs or devices may fall under different recall authorities.
How Does the Mandatory Recall Process Work?
The FDA generally provides the responsible person with an opportunity to voluntarily stop distribution and recall the affected product before proceeding with mandatory action.
If the company declines or fails to take the necessary voluntary action, the FDA may issue an order requiring distribution to cease immediately.
The responsible person must then be given an opportunity for an informal hearing. If a hearing is granted, it must take place within 10 days after the order is issued.
After the opportunity for a hearing, the FDA may withdraw the order, maintain the distribution restriction or amend the order to require a formal product recall.
The agency may also require notifications to manufacturers, distributors, importers, retailers and consumers.
What Evidence May the FDA Consider?
The guidance identifies several types of information that may be relevant when evaluating whether a mandatory recall is necessary.
These include:
- Product testing and laboratory results, including relevant raw material or finished-product analyses.
- Safety observations made during manufacturing facility inspections.
- Serious adverse event information and consumer complaints.
- Evidence of contamination or potentially unsafe manufacturing conditions.
- Risks to vulnerable consumer populations.
The FDA also explains circumstances under which products may be considered adulterated or misbranded, including certain failures involving safety substantiation or misleading labelling.
What Does This Mean for Cosmetics Companies?
The final guidance does not introduce a new blanket recall requirement for all cosmetic products. Instead, it explains the FDA’s implementation of authority already established under MoCRA.
The FDA continues to encourage voluntary recalls when companies identify products that violate applicable requirements.
Industry Perspective
For cosmetics brands, manufacturers and supply chain partners serving the U.S. market, the guidance reinforces the practical importance of product safety documentation, traceability, complaint handling and effective recall procedures.
For an ingredient-level example of reviewing supplier specifications, batch testing data and quality records, see NOYAIN’s PDRN Quality Guide. Ingredient quality documentation is only one component of finished-product compliance.
NOYAIN follows international cosmetics regulatory developments to stay informed about evolving quality and documentation expectations across global markets. Explore our cosmetic ingredient sourcing and formulation support.
